BioSpace News Archive

NOCDURNA is the first and only sublingual tablet for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to void.1

Data Demonstrate Sofosbuvir-Based Regimens Achieve High Cure Rates in Hepatitis C Patient Populations with Unmet Need

In Post-Hoc Pooled Analysis of North American Studies, Investigational Agent Terlipressin Associated With Improvement in Survival in Patients with Hepatorenal Syndrome Type 1 with Low Baseline Mean Arterial Pressure

Addiction Treatment Company Celebrates 10th-Year as New Facility Opens

According to data compiled by Grand View Research, the global biotechnology market is expected to reach USD 727.1 Billion by 2025.

Data Show That ALG.APV-527 Selectively Activates and Enhances Tumor-directed T-cell and Natural Killer (NK) Cell Responses

miRagen Named Company of the Year, Inscripta Honored as Rising Star

Jazz Pharmaceuticals plc today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency for solriamfetol, a selective dopamine and norepinephrine reuptake inhibitor, as a treatment to improve wakefulness and reduce excessive daytime sleepiness (EDS) in adult patients with narcolepsy (with or without cataplexy) or obstructive sleep apnea (OSA).

First presentation of LENVIMA and KEYTRUDA combination data in patients with metastatic non-small cell lung cancer, metastatic melanoma and metastatic urothelial carcinoma from Study 111/KEYNOTE-146

Bruker Corporation today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.04 per share on the Company’s common stock.